Drug Strategy Blocks a Leading Driver of Cancer according to new Nature paper by MSTP student Jonathan Ostrem

As described in a recent Nature paper, MSTP student Jonathan Ostrem has succeeded in making small molecules that irreversibly target a mutant form of this protein, called ras, without binding to the normal form. This feature distinguishes the molecules from all other targeted drug treatments in cancer.